Structural determination of the complement inhibitory domain of Borrelia burgdorferi BBK32 provides insight into classical pathway complement evasion by Lyme disease spirochetes.


Journal

PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921

Informations de publication

Date de publication:
03 2019
Historique:
received: 19 11 2018
accepted: 26 02 2019
revised: 02 04 2019
pubmed: 22 3 2019
medline: 25 4 2019
entrez: 22 3 2019
Statut: epublish

Résumé

The carboxy-terminal domain of the BBK32 protein from Borrelia burgdorferi sensu stricto, termed BBK32-C, binds and inhibits the initiating serine protease of the human classical complement pathway, C1r. In this study we investigated the function of BBK32 orthologues of the Lyme-associated Borrelia burgdorferi sensu lato complex, designated BAD16 from B. afzelii strain PGau and BGD19 from B. garinii strain IP90. Our data show that B. afzelii BAD16-C exhibits BBK32-C-like activities in all assays tested, including high-affinity binding to purified C1r protease and C1 complex, and potent inhibition of the classical complement pathway. Recombinant B. garinii BGD19-C also bound C1 and C1r with high-affinity yet exhibited significantly reduced in vitro complement inhibitory activities relative to BBK32-C or BAD16-C. Interestingly, natively produced BGD19 weakly recognized C1r relative to BBK32 and BAD16 and, unlike these proteins, BGD19 did not confer significant protection from serum killing. Site-directed mutagenesis was performed to convert BBK32-C to resemble BGD19-C at three residue positions that are identical between BBK32 and BAD16 but different in BGD19. The resulting chimeric protein was designated BXK32-C and this BBK32-C variant mimicked the properties observed for BGD19-C. To query the disparate complement inhibitory activities of BBK32 orthologues, the crystal structure of BBK32-C was solved to 1.7Å limiting resolution. BBK32-C adopts an anti-parallel four-helix bundle fold with a fifth alpha-helix protruding from the helical core. The structure revealed that the three residues targeted in the BXK32-C chimera are surface-exposed, further supporting their potential relevance in C1r binding and inhibition. Additional binding assays showed that BBK32-C only recognized C1r fragments containing the serine protease domain. The structure-function studies reported here improve our understanding of how BBK32 recognizes and inhibits C1r and provide new insight into complement evasion mechanisms of Lyme-associated spirochetes of the B. burgdorferi sensu lato complex.

Identifiants

pubmed: 30897158
doi: 10.1371/journal.ppat.1007659
pii: PPATHOGENS-D-18-02228
pmc: PMC6445466
doi:

Substances chimiques

Bacterial Proteins 0
Recombinant Proteins 0
p35 antigen, Borrelia 0
Complement System Proteins 9007-36-7
Complement C1r EC 3.4.21.41

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1007659

Subventions

Organisme : NIAID NIH HHS
ID : R21 AI133367
Pays : United States

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

J Clin Microbiol. 2003 Aug;41(8):3905-10
pubmed: 12904415
mBio. 2013 Aug 13;4(4):
pubmed: 23943762
Infect Immun. 2004 Mar;72(3):1580-6
pubmed: 14977964
Infect Immun. 2001 Dec;69(12):7800-9
pubmed: 11705962
Infect Immun. 1998 Mar;66(3):1248-51
pubmed: 9488421
Cell Rep. 2016 Sep 6;16(10):2593-2604
pubmed: 27568563
Mol Microbiol. 2015 Apr;96(1):68-83
pubmed: 25560615
J Biol Chem. 2013 Aug 30;288(35):25229-25243
pubmed: 23861404
Front Immunol. 2016 Sep 26;7:385
pubmed: 27725820
J Immunol. 2003 Mar 15;170(6):3214-22
pubmed: 12626580
J Mol Biol. 2018 Jul 20;430(15):2237-2243
pubmed: 29258817
J Infect Dis. 2010 Aug 15;202(3):490-8
pubmed: 20565259
Front Immunol. 2015 May 26;6:257
pubmed: 26074922
Nature. 1997 Dec 11;390(6660):580-6
pubmed: 9403685
J Infect Dis. 1996 Jul;174(1):97-104
pubmed: 8656020
J Immunol. 2001 Nov 1;167(9):5202-8
pubmed: 11673533
Biochim Biophys Acta. 1980 Nov 6;616(1):116-29
pubmed: 6254570
Mol Microbiol. 2011 Oct;82(1):99-113
pubmed: 21854463
Mol Immunol. 2010 Mar;47(6):1299-305
pubmed: 20022381
Infect Immun. 1993 May;61(5):2192-5
pubmed: 8478109
Proc Natl Acad Sci U S A. 2013 Aug 20;110(34):13916-20
pubmed: 23922389
Infect Immun. 1997 Apr;65(4):1228-36
pubmed: 9119456
Nat Rev Microbiol. 2012 Jan 09;10(2):87-99
pubmed: 22230951
Proc Natl Acad Sci U S A. 2018 Jan 23;115(4):768-773
pubmed: 29311313
PLoS Pathog. 2016 Jan 25;12(1):e1005404
pubmed: 26808924
J Immunol. 2016 Sep 15;197(6):2051-60
pubmed: 27591336
Cell Microbiol. 2017 Dec;19(12):
pubmed: 28873507
Acta Crystallogr D Biol Crystallogr. 2013 Nov;69(Pt 11):2276-86
pubmed: 24189240
PLoS Pathog. 2013;9(12):e1003816
pubmed: 24348255
Methods Enzymol. 1997;276:307-26
pubmed: 27754618
Nat Rev Microbiol. 2014 Jan;12(1):49-62
pubmed: 24336184
Infect Immun. 2001 Jun;69(6):3685-91
pubmed: 11349031
Infect Immun. 2006 Jan;74(1):435-41
pubmed: 16368999
Infect Genet Evol. 2011 Oct;11(7):1545-63
pubmed: 21843658
J Bacteriol. 2007 Jan;189(2):437-45
pubmed: 17098904
Front Immunol. 2018 May 07;9:959
pubmed: 29867944
Vaccine. 2008 Dec 30;26 Suppl 8:I75-8
pubmed: 19388169
Nat Immunol. 2017 Nov 16;18(12):1288-1298
pubmed: 29144501
Infect Immun. 2003 Jun;71(6):3597-602
pubmed: 12761145
Front Immunol. 2015 Jun 02;6:262
pubmed: 26082779
Methods Mol Biol. 2018;1690:183-200
pubmed: 29032546
Front Immunol. 2017 Feb 20;8:116
pubmed: 28265270
Methods Mol Biol. 2008;426:419-35
pubmed: 18542881
Proc Natl Acad Sci U S A. 2017 Apr 25;114(17):E3490-E3498
pubmed: 28396443
Front Immunol. 2017 May 18;8:571
pubmed: 28572805
Mol Microbiol. 2012 Dec;86(5):1116-31
pubmed: 23095033
Trends Microbiol. 2002 Feb;10(2):74-9
pubmed: 11827808
Infect Immun. 2009 Jan;77(1):300-6
pubmed: 19001079
Protein Expr Purif. 2006 Mar;46(1):23-32
pubmed: 16260150
Front Microbiol. 2017 Jan 31;8:89
pubmed: 28197139
FEMS Immunol Med Microbiol. 2005 Feb 1;43(2):165-72
pubmed: 15681146
Mol Microbiol. 2006 Mar;59(5):1591-601
pubmed: 16468997
Cell Microbiol. 2015 Jun;17(6):860-75
pubmed: 25486989
J Infect Dis. 2004 Apr 15;189(8):1515-23
pubmed: 15073690
JAMA. 2013 Sep 18;310(11):1110
pubmed: 24045727
J Biol Chem. 2014 Aug 8;289(32):22490-9
pubmed: 24962582
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501
pubmed: 20383002
Nat Rev Microbiol. 2008 Feb;6(2):132-42
pubmed: 18197169
Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10037-41
pubmed: 11517324
Ticks Tick Borne Dis. 2013 Feb;4(1-2):26-34
pubmed: 23219363
Mol Immunol. 2003 Jan;39(11):655-68
pubmed: 12493641
EMBO J. 2002 Feb 1;21(3):231-9
pubmed: 11823416
J Bacteriol. 1996 Jun;178(12):3508-16
pubmed: 8655548
Biochem J. 1985 Jan 1;225(1):135-42
pubmed: 2983658
Anal Biochem. 2006 Feb 1;349(1):136-47
pubmed: 16337141
Infect Immun. 1995 Apr;63(4):1573-80
pubmed: 7890424
Science. 2016 May 6;352(6286):680-7
pubmed: 27151862
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):213-21
pubmed: 20124702
Acta Crystallogr D Biol Crystallogr. 2002 Nov;58(Pt 11):1948-54
pubmed: 12393927
Infect Immun. 2014 Jun;82(6):2520-31
pubmed: 24686059
J Biol Chem. 2004 Oct 1;279(40):41706-14
pubmed: 15292204
Nucleic Acids Res. 2018 Jul 2;46(W1):W296-W303
pubmed: 29788355
J Immunol. 2002 Oct 1;169(7):3847-53
pubmed: 12244181
PLoS One. 2009;4(4):e5412
pubmed: 19404402
Infect Immun. 2003 Jun;71(6):3587-96
pubmed: 12761144
PLoS Pathog. 2018 May 29;14(5):e1007106
pubmed: 29813137
Science. 2018 Feb 16;359(6377):794-797
pubmed: 29449492
Adv Exp Med Biol. 2012;946:113-33
pubmed: 21948365
Mol Microbiol. 2016 Jan;99(2):407-24
pubmed: 26434356
PLoS Pathog. 2015 Jul 02;11(7):e1004976
pubmed: 26136236
PLoS One. 2016 Jul 19;11(7):e0159118
pubmed: 27434228
Bioinformatics. 2011 Feb 1;27(3):343-50
pubmed: 21134891
Mol Microbiol. 1998 Dec;30(5):1003-15
pubmed: 9988477
Infect Immun. 2001 Jun;69(6):4129-33
pubmed: 11349087
Nat Immunol. 2010 Sep;11(9):785-97
pubmed: 20720586
Semin Immunopathol. 2018 Jan;40(1):37-48
pubmed: 28842749
Infect Immun. 2015 Sep;83(9):3693-703
pubmed: 26150534

Auteurs

Jialei Xie (J)

Department of Microbial Pathogenesis and Immunology, College of Medicine, Texas A&M Health Sciences Center, Bryan, Texas, United States of America.

Hui Zhi (H)

Department of Microbial Pathogenesis and Immunology, College of Medicine, Texas A&M Health Sciences Center, Bryan, Texas, United States of America.

Ryan J Garrigues (RJ)

Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, Greenville, North Carolina, United States of America.

Andrew Keightley (A)

Division of Molecular Biology and Biochemistry, School of Biological Sciences, University of Missouri-Kansas City, Kansas City, Missouri, United States of America.

Brandon L Garcia (BL)

Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, Greenville, North Carolina, United States of America.

Jon T Skare (JT)

Department of Microbial Pathogenesis and Immunology, College of Medicine, Texas A&M Health Sciences Center, Bryan, Texas, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH